AU734928B2 - 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors - Google Patents

4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors Download PDF

Info

Publication number
AU734928B2
AU734928B2 AU67960/98A AU6796098A AU734928B2 AU 734928 B2 AU734928 B2 AU 734928B2 AU 67960/98 A AU67960/98 A AU 67960/98A AU 6796098 A AU6796098 A AU 6796098A AU 734928 B2 AU734928 B2 AU 734928B2
Authority
AU
Australia
Prior art keywords
dihydro
pyridyl
quinazolinone
trifluoromethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU67960/98A
Other languages
English (en)
Other versions
AU6796098A (en
Inventor
Jeffrey W. Corbett
Soo Sung Ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU6796098A publication Critical patent/AU6796098A/en
Application granted granted Critical
Publication of AU734928B2 publication Critical patent/AU734928B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU67960/98A 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors Ceased AU734928B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US08/838540 1997-04-09
US7132298P 1998-01-14 1998-01-14
US60/071322 1998-01-14
PCT/US1998/006733 WO1998045276A2 (fr) 1997-04-09 1998-04-07 4,4-disubstituees-3,4-dihydro-2(1h)-quinazolinones utilisees comme inhibiteurs de la transcriptase inverse du vih

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU73713/01A Division AU7371301A (en) 1997-04-09 2001-09-19 4,4-disubstituted-3,4-dihydro-2-)1H)- quinazolinones useful as HIV reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
AU6796098A AU6796098A (en) 1998-10-30
AU734928B2 true AU734928B2 (en) 2001-06-28

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67960/98A Ceased AU734928B2 (en) 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors

Country Status (19)

Country Link
EP (1) EP0973753A2 (fr)
JP (1) JP2002504095A (fr)
KR (1) KR20010006146A (fr)
CN (1) CN1252063A (fr)
AR (1) AR012340A1 (fr)
AU (1) AU734928B2 (fr)
BR (1) BR9808513A (fr)
CA (1) CA2284996A1 (fr)
EA (1) EA001991B1 (fr)
EE (1) EE9900452A (fr)
HR (1) HRP980143A2 (fr)
HU (1) HUP0001446A3 (fr)
IL (1) IL132188A0 (fr)
NO (1) NO314936B1 (fr)
NZ (1) NZ500592A (fr)
PL (1) PL336305A1 (fr)
SK (1) SK137899A3 (fr)
TW (1) TW587078B (fr)
WO (1) WO1998045276A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050253A1 (fr) * 1998-03-27 1999-10-07 Du Pont Pharmaceuticals Company 3,4-dihydro-2(1h)-quinazolinthiones substitues en 4,4, leur preparation et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
AU6508899A (en) 1998-10-13 2000-05-01 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
US6225317B1 (en) * 1998-11-19 2001-05-01 Dupont Pharmaceuticals Company Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone
HRP990359A2 (en) * 1998-11-19 2000-08-31 Du Pont Pharm Co A process for the preparation of quinazolinones
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6555686B2 (en) 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
AU2001249161A1 (en) * 2000-03-23 2001-10-03 Bristol-Myers Squibb Pharma Company Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (fr) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Element penetrant peu douloureux
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
EP1680014A4 (fr) 2003-10-14 2009-01-21 Pelikan Technologies Inc Procede et appareil fournissant une interface-utilisateur variable
WO2005065414A2 (fr) 2003-12-31 2005-07-21 Pelikan Technologies, Inc. Procede et appareil permettant d'ameliorer le flux fluidique et le prelevement d'echantillons
WO2006011062A2 (fr) 2004-05-20 2006-02-02 Albatros Technologies Gmbh & Co. Kg Hydrogel imprimable pour biocapteurs
EP1765194A4 (fr) 2004-06-03 2010-09-29 Pelikan Technologies Inc Procede et appareil pour la fabrication d'un dispositif d'echantillonnage de liquides
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
WO2009126900A1 (fr) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Procédé et appareil pour dispositif de détection d’analyte
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (zh) * 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
EP3173096A1 (fr) * 2011-04-06 2017-05-31 Biovaxim Limited Compositions pharmaceutiques pour prévenir et/ou traiter une maladie vih chez l'homme
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (fr) 2013-01-22 2014-07-31 Novartis Ag Composés de purinone substitués
MX2015016344A (es) 2013-05-27 2016-03-01 Novartis Ag Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PL3004112T3 (pl) 2013-05-28 2018-02-28 Novartis Ag Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EP3071571A1 (fr) 2013-11-21 2016-09-28 Novartis AG Dérivés de pyrrolopyrrolone et leur utilisation en tant qu'inhibiteurs de protéines bet

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0530994A1 (fr) * 1991-08-16 1993-03-10 Merck & Co. Inc. Dérivés de quinazoline utilisés comme inhibiteurs de transcriptase inverse de HIV

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
WO1993022292A1 (fr) * 1992-05-07 1993-11-11 Merck & Co., Inc. Nouvelles quinazolines inhibant la transcriptase inverse du vih
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (de) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0530994A1 (fr) * 1991-08-16 1993-03-10 Merck & Co. Inc. Dérivés de quinazoline utilisés comme inhibiteurs de transcriptase inverse de HIV

Also Published As

Publication number Publication date
BR9808513A (pt) 2000-05-23
NZ500592A (en) 2001-09-28
NO314936B1 (no) 2003-06-16
WO1998045276A3 (fr) 1999-01-14
AU6796098A (en) 1998-10-30
EP0973753A2 (fr) 2000-01-26
EA199900907A1 (ru) 2000-04-24
IL132188A0 (en) 2001-03-19
NO994904L (no) 1999-12-01
TW587078B (en) 2004-05-11
EA001991B1 (ru) 2001-10-22
AR012340A1 (es) 2000-10-18
CA2284996A1 (fr) 1998-10-15
SK137899A3 (en) 2000-05-16
KR20010006146A (ko) 2001-01-26
HRP980143A2 (en) 1999-02-28
HUP0001446A2 (hu) 2001-05-28
CN1252063A (zh) 2000-05-03
JP2002504095A (ja) 2002-02-05
EE9900452A (et) 2000-04-17
PL336305A1 (en) 2000-06-19
HUP0001446A3 (en) 2001-11-28
NO994904D0 (no) 1999-10-08
WO1998045276A2 (fr) 1998-10-15

Similar Documents

Publication Publication Date Title
AU734928B2 (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
EP0929533B1 (fr) 4,4-disubstitue-1,4-dihydro-2h-3,1-benzoxazine-2-ones utiles en tant qu'inhibiteurs de transcriptase inverse du vih et intermediaires et procedes de fabrication correspondants
WO2001029037A2 (fr) Composes tricycliques utiles comme inhibiteurs de la transcriptase inverse du vih
US6124302A (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
US20020177603A1 (en) Tricyclic compounds useful as HIV reverse transcriptase inhibitors
US6127375A (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones useful as HIV reverse transcriptase inhibitors
US6204262B1 (en) 1,3-Benzodiazepin-2-ones and 1,3-Benzoxazepin-2-ones useful as HIV reverse transcriptase inhibitors
US6489320B1 (en) 5, 5-disubstituted-1, 5-dihydro-4, 1-benzoxazepin-2 (3H)-ones useful as HIV reverse transcriptase inhibitors
US6090821A (en) Substituted quinolin-2 (1H)-ones useful as HIV reverse transcriptase inhibitors
US6946469B2 (en) Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
US20040063734A1 (en) 4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors
AU7371301A (en) 4,4-disubstituted-3,4-dihydro-2-)1H)- quinazolinones useful as HIV reverse transcriptase inhibitors
US6265406B1 (en) Substituted quinolin-2 (1H) -ones useful as HIV reverse transcriptase inhibitors
US6462037B1 (en) 1,4-benzodiazepin-2-ones useful as HIV reverse transcriptase inhibitors
US7015214B2 (en) Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazepine as HIV reverse transcriptase inhibitors
CZ352499A3 (cs) 4,4-Disubstituované-3,4-dihydro-2 (1H)- chinazolinony vhodné jako inhibitory HIV reverzní transkriptázy
MXPA99008909A (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
AU2002254652A1 (en) Tricyclic compounds useful as HIV reverse transcriptase inhibitors
CA2330110A1 (fr) 1,3-benzodiazepin-2-ones et 1,3-benzoxazepin-2-ones utilisees comme inhibiteurs de la reverse-transcriptase du vih

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired